Drug Combination Details
| General Information of the Combination (ID: C39202) | |||||
|---|---|---|---|---|---|
| Name | Vincristine NP Info | + | Combretastatin A-4 phosphate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TRIM26 | Molecule Info | |||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | Rats received single I.P injection of Diethylnitrosamine (DENA) 200 mg/kg body weight, freshly dissolved in sterile 0.9% saline, as an inducer for hepatocellular carcinoma. | |||||
| Experimental
Result(s) |
CA4-P showed a potential anti-cancer activity against hepatocellular carcinoma and this effect was greatly enhanced by co-administration with vincristine. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Enhanced anticancer effect of Combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma. Biomed Pharmacother. 2017 May;89:36-46. | |||
